[go: up one dir, main page]

CL2016000621A1 - Formulación que comprende un adenovirus recombinante un tampón citrato hidroxipropil-beta-ciclodextrina una sal un detergente no iónico en la que dicha formulación tiene un ph que oscila entre 5.5-6,5. método de conservación de un adenovirus - Google Patents

Formulación que comprende un adenovirus recombinante un tampón citrato hidroxipropil-beta-ciclodextrina una sal un detergente no iónico en la que dicha formulación tiene un ph que oscila entre 5.5-6,5. método de conservación de un adenovirus

Info

Publication number
CL2016000621A1
CL2016000621A1 CL2016000621A CL2016000621A CL2016000621A1 CL 2016000621 A1 CL2016000621 A1 CL 2016000621A1 CL 2016000621 A CL2016000621 A CL 2016000621A CL 2016000621 A CL2016000621 A CL 2016000621A CL 2016000621 A1 CL2016000621 A1 CL 2016000621A1
Authority
CL
Chile
Prior art keywords
formulation
adenovirus
cyclodextrin
hydroxypropyl
beta
Prior art date
Application number
CL2016000621A
Other languages
English (en)
Inventor
Janik Adriaansen
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49212683&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016000621(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of CL2016000621A1 publication Critical patent/CL2016000621A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Formulaciones para adenovirus que comprende a) un adenovirus recombinante; b) un tampón de citrato; c) hidroxipropil-beta-ciclodextrina (HBCD); d) una sal; e) un detergente no iónico; en la que dicha formulación tiene un pH que oscila entre 5.5-6,5.
CL2016000621A 2013-09-19 2016-03-15 Formulación que comprende un adenovirus recombinante un tampón citrato hidroxipropil-beta-ciclodextrina una sal un detergente no iónico en la que dicha formulación tiene un ph que oscila entre 5.5-6,5. método de conservación de un adenovirus CL2016000621A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13185200 2013-09-19

Publications (1)

Publication Number Publication Date
CL2016000621A1 true CL2016000621A1 (es) 2016-11-25

Family

ID=49212683

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000621A CL2016000621A1 (es) 2013-09-19 2016-03-15 Formulación que comprende un adenovirus recombinante un tampón citrato hidroxipropil-beta-ciclodextrina una sal un detergente no iónico en la que dicha formulación tiene un ph que oscila entre 5.5-6,5. método de conservación de un adenovirus

Country Status (33)

Country Link
US (3) US9974737B2 (es)
EP (1) EP3046536B1 (es)
JP (1) JP6013654B2 (es)
KR (1) KR102258348B1 (es)
CN (2) CN105530917B (es)
AP (1) AP2016009154A0 (es)
AU (1) AU2014323230B2 (es)
BR (1) BR112016005761B1 (es)
CA (1) CA2923352C (es)
CL (1) CL2016000621A1 (es)
CY (1) CY1122796T1 (es)
DK (1) DK3046536T3 (es)
EA (1) EA036046B1 (es)
ES (1) ES2711115T3 (es)
HR (1) HRP20182159T1 (es)
HU (1) HUE041791T2 (es)
IL (1) IL244572A (es)
LT (1) LT3046536T (es)
ME (1) ME03324B (es)
MX (1) MX369156B (es)
MY (1) MY181190A (es)
NZ (1) NZ717156A (es)
PE (1) PE20160527A1 (es)
PH (1) PH12016500316B1 (es)
PL (1) PL3046536T3 (es)
PT (1) PT3046536T (es)
RS (1) RS58393B1 (es)
SG (1) SG11201601181SA (es)
SI (1) SI3046536T1 (es)
SM (1) SMT201900092T1 (es)
TR (1) TR201900274T4 (es)
WO (1) WO2015040002A1 (es)
ZA (1) ZA201601919B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201508567XA (en) 2013-04-25 2015-11-27 Crucell Holland Bv Stabilized soluble prefusion rsv f polypeptides
US9585971B2 (en) 2013-09-13 2017-03-07 California Institute Of Technology Recombinant AAV capsid protein
MX369156B (es) * 2013-09-19 2019-10-30 Janssen Vaccines & Prevention Bv Formulaciones de adenovirus mejoradas.
EA039065B1 (ru) 2015-07-07 2021-11-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
US10457708B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
HK1254838A1 (zh) * 2015-10-06 2019-07-26 Janssen Vaccines & Prevention B.V. 用於预防生物制品的塑料诱导降解的方法
AU2016366549B2 (en) 2015-12-11 2022-11-10 California Institute Of Technology Targeting peptides for directing adeno-associated viruses (AAVs)
CN109069612A (zh) 2016-04-05 2018-12-21 扬森疫苗与预防公司 针对rsv的疫苗
EP3808374A1 (en) 2016-04-05 2021-04-21 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f proteins for use in the prophylaxis of rsv infection
PE20190110A1 (es) 2016-05-30 2019-01-15 Janssen Vaccines And Prevention B V Proteinas f de prefusion del vrs estabilizadas
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
CA3061278A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
BR112020004143A2 (pt) 2017-09-15 2020-09-01 Janssen Vaccines & Prevention B.V. método para a indução segura de imunidade contra vírus sincicial respiratório (rsv)
KR20210084459A (ko) 2018-09-26 2021-07-07 캘리포니아 인스티튜트 오브 테크놀로지 표적화된 유전자 요법을 위한 아데노-연관 바이러스 조성물
SG11202103151RA (en) 2018-09-28 2021-04-29 Voyager Therapeutics Inc Frataxin expression constructs having engineered promoters and methods of use thereof
PH12021550974A1 (en) 2018-11-13 2022-05-02 Janssen Vaccines & Prevention Bv Stablized pre-fusion rsv f proteins
CN113438943A (zh) * 2019-01-09 2021-09-24 辛克库姆公司 稳定的无包膜病毒组合物
EP4255503A4 (en) * 2020-12-04 2025-08-06 COMPOSITIONS AND METHODS OF USE THEREOF
WO2023282796A2 (en) * 2021-07-08 2023-01-12 Limited Liability Company «ANABION» Pharmaceutical composition of non-enveloped virus
WO2023240196A1 (en) * 2022-06-08 2023-12-14 Gritstone Bio, Inc. Compositions and methods of use thereof
EP4338727A1 (en) 2022-09-14 2024-03-20 Roquette Freres Adenovirus formulations
KR20250078975A (ko) * 2022-10-11 2025-06-04 메이라지티엑스 유케이 Ii 리미티드 Aav 유전자 요법을 위한 제형
WO2025218651A1 (zh) * 2024-04-15 2025-10-23 康希诺生物股份公司 一种重组腺病毒载体疫苗制剂及其制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
WO1995034671A1 (en) 1994-06-10 1995-12-21 Genvec, Inc. Complementary adenoviral vector systems and cell lines
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
EP1445322B2 (en) 1995-06-15 2012-06-06 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
WO2000029024A1 (en) * 1998-11-16 2000-05-25 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6225289B1 (en) * 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
JP5118798B2 (ja) * 2000-03-07 2013-01-16 メルク・シャープ・エンド・ドーム・コーポレイション アデノウイルス製剤
US7456009B2 (en) * 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
WO2003049763A1 (en) * 2001-12-12 2003-06-19 Fh Faulding & Co Limited Composition for the preservation of viruses
SI1456377T1 (sl) * 2001-12-20 2019-09-30 Merck Sharp & Dohme Corp. Sestavki SYN3 in postopki
US20030180936A1 (en) * 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
ES2335657T3 (es) 2002-04-25 2010-03-31 Crucell Holland B.V. Medios y metodos para la produccion de vectores de adenovirus.
NZ539813A (en) 2002-12-17 2008-04-30 Crucell Holland Bv A replication defective recombinant adenovirus comprising a antigenic determinant of Plasmodium falciparum wherein the antigenic determinant is SEQ ID 6
CN101396555A (zh) 2003-06-04 2009-04-01 坎基股份有限公司 用于干扰素治疗的方法和组合物
US20050031579A1 (en) * 2003-06-30 2005-02-10 Canji, Inc. Polymer encapsulation of adenoviruses
EP1692279A4 (en) * 2003-11-19 2006-12-27 Merck & Co Inc VIRUS PREPARATIONS CONTAINING A CONSERVATIVE
KR101386690B1 (ko) * 2004-03-04 2014-04-22 도쿠리츠교세이호진 고쿠리츠간켄큐센터 래트 배아 줄기 세포
NZ555907A (en) 2004-11-16 2009-12-24 Aeras Global Tb Vaccine Found Multivalent vaccines comprising recombinant viral vectors
CN1883707A (zh) * 2006-05-19 2006-12-27 吉林大学 重组腺病毒的冻干制剂及其制备方法
GB0715723D0 (en) * 2007-08-11 2007-09-19 Ark Therapeutics Ltd Formulation
EP2473191B1 (en) * 2009-09-04 2017-08-23 XOMA Technology Ltd. Antibody coformulations
GB201002419D0 (en) 2010-02-12 2010-03-31 Isis Innovation Stable live vaccine formulations
WO2012110971A2 (en) 2011-02-17 2012-08-23 Promed Exports Pvt. Ltd. Method and composition to retard sorption of preservatives to plastics
MX369156B (es) * 2013-09-19 2019-10-30 Janssen Vaccines & Prevention Bv Formulaciones de adenovirus mejoradas.
CN104027815A (zh) 2014-06-12 2014-09-10 中国农业科学院兰州畜牧与兽药研究所 一种丹参酮包合液及其制备方法和应用
HK1254838A1 (zh) 2015-10-06 2019-07-26 Janssen Vaccines & Prevention B.V. 用於预防生物制品的塑料诱导降解的方法

Also Published As

Publication number Publication date
EA201690613A1 (ru) 2016-08-31
LT3046536T (lt) 2019-03-12
IL244572A (en) 2017-02-28
RS58393B1 (sr) 2019-04-30
JP2016530220A (ja) 2016-09-29
CN105530917A (zh) 2016-04-27
MX2016003414A (es) 2016-06-30
SI3046536T1 (sl) 2019-05-31
US11484494B2 (en) 2022-11-01
PH12016500316A1 (en) 2016-05-02
US20190240146A1 (en) 2019-08-08
CA2923352A1 (en) 2015-03-26
PT3046536T (pt) 2019-02-25
SMT201900092T1 (it) 2019-02-28
AP2016009154A0 (en) 2016-04-30
HRP20182159T1 (hr) 2019-02-22
EP3046536B1 (en) 2018-11-28
HUE041791T2 (hu) 2019-05-28
MX369156B (es) 2019-10-30
JP6013654B2 (ja) 2016-10-25
ZA201601919B (en) 2017-06-28
PE20160527A1 (es) 2016-05-20
US20180235871A1 (en) 2018-08-23
AU2014323230A1 (en) 2016-03-17
KR20160055180A (ko) 2016-05-17
US10272032B2 (en) 2019-04-30
AU2014323230B2 (en) 2017-05-25
PH12016500316B1 (en) 2019-02-01
EA036046B1 (ru) 2020-09-18
MY181190A (en) 2020-12-21
WO2015040002A1 (en) 2015-03-26
SG11201601181SA (en) 2016-04-28
ME03324B (me) 2019-10-20
DK3046536T3 (en) 2019-03-11
BR112016005761B1 (pt) 2022-09-20
ES2711115T3 (es) 2019-04-30
CY1122796T1 (el) 2021-05-05
CN105530917B (zh) 2020-06-05
CA2923352C (en) 2022-05-03
CN111514314A (zh) 2020-08-11
KR102258348B1 (ko) 2021-05-31
NZ717156A (en) 2022-04-29
PL3046536T3 (pl) 2019-06-28
IL244572A0 (en) 2016-04-21
EP3046536A1 (en) 2016-07-27
US9974737B2 (en) 2018-05-22
TR201900274T4 (tr) 2019-02-21
US20160199426A1 (en) 2016-07-14
BR112016005761A2 (es) 2017-08-01

Similar Documents

Publication Publication Date Title
CL2016000621A1 (es) Formulación que comprende un adenovirus recombinante un tampón citrato hidroxipropil-beta-ciclodextrina una sal un detergente no iónico en la que dicha formulación tiene un ph que oscila entre 5.5-6,5. método de conservación de un adenovirus
AR086025A1 (es) Preparaciones para composiciones de limpieza multiuso
ECSP13013094A (es) Composiciones de limpieza de sal colina
AR105470A1 (es) Métodos para inducir una respuesta inmune
CY1120937T1 (el) Φαρμακευτικη μορφοποιηση αντισωματος anti-tnf-αλφα
MX2018005402A (es) Composiciones de tratamiento que proporcionan un beneficio antimicrobiano.
ECSP13013093A (es) Composiciones líquidas de limpieza de sal
CR20150482A (es) Anticuerpos e inmunoconjugados anti-b7-h4
CR20150048A (es) Anticuerpos e inmunoconjugados anti-cd22
AR093645A1 (es) Una formulacion estabilizada de pemetrexed
MX2017003121A (es) Formulaciones de anticuerpos.
AR102203A1 (es) Composiciones para el cuidado oral que comprenden zinc, arginina y serina
CL2016003223A1 (es) Sistema y método para estimar una carga de una maquina industrial
BR112018002410A2 (pt) sistema conservante
CL2014002414A1 (es) Composicion farmaceutica inyectable que comprende ibuprofeno, una solucion acuosa y un agente solubilizante seleccionado de fosfatos de sodio, de potasio, carbonatos de sodio, de potasio y/o combinaciones de ellos.
CR20150310A (es) Solución para preservar conductos vasculares
MX390924B (es) Detergentes y agentes de limpieza que comprenden una combinación de amilasa y proteasa.
CO2017007316A2 (es) Formulación farmacéutica
BR112016027898A2 (pt) método, entidade de recepção, e, meio legível por computador para ocultação de perda de quadro
AR106559A1 (es) Suspensión acuosa para administración oral y método para su preparación
MX2019005557A (es) Composicion para el cuidado bucal.
MX2017014985A (es) Dentifrico espumante con agentes desensibilizantes.
BR112013019924A8 (pt) Composições para cuidado oral
CL2018002201A1 (es) Procedimiento para disolución selectiva utilizando tensoactivo no ionico.
UY34638A (es) Empaque normalizado y método para su elaboración.